Issue 18, 2025, Issue in Progress

Thermo-responsive methylcellulose/hyaluronic acid–mesalamine hydrogel in targeted drug delivery for ulcerative colitis

Abstract

Current treatments for ulcerative colitis (UC), including mesalamine (Me) enemas, face limitations such as poor colonic retention, systemic side effects, and suboptimal patient compliance. To address these challenges, this study developed a thermo-responsive hydrogel combining hyaluronic acid–mesalamine (HA–Me) conjugates with methylcellulose (MC), providing a targeted and sustained drug delivery platform for UC treatment. HA–Me conjugates were synthesized via a nucleophilic addition–elimination reaction, with FT-IR and 1H-NMR confirming successful conjugation and a grafting ratio of 12.45%. Rheological analysis revealed a lower critical solution temperature (LCST) of 36.7–37.7 °C, ensuring gelation at body temperature when the MC concentration was 5–7 wt%. The optimized hydrogel exhibits intestinal retention properties, thereby improving drug bioavailability. The results confirmed that this hydrogel not only improved drug release time but also provided a protective barrier for inflamed wounds, facilitating wound healing, reducing the risk of reinfection, and improving medical compliance. Its mucoadhesive properties further supported effective drug delivery and localized therapeutic effects. This study highlights the potential of the MC/HA–Me hydrogel as a platform for overcoming the limitations of conventional UC treatments, offering opportunities for tailored therapeutic applications and future clinical development.

Graphical abstract: Thermo-responsive methylcellulose/hyaluronic acid–mesalamine hydrogel in targeted drug delivery for ulcerative colitis

Article information

Article type
Paper
Submitted
13 Jan 2025
Accepted
17 Apr 2025
First published
01 May 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 14126-14135

Thermo-responsive methylcellulose/hyaluronic acid–mesalamine hydrogel in targeted drug delivery for ulcerative colitis

S. Kuo, P. Wu, S. Huang, Y. Hsu and J. Huang, RSC Adv., 2025, 15, 14126 DOI: 10.1039/D5RA00216H

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements